Erratum: A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase iii clinical trial using limited hormonal therapy (The Journal of Urology (2005) 173 (5) (1567–1571) (S0022534705606246) (10.1097/01.ju.0000154780.72631.85));A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy

Journal of Urology

Volumn 173, Issue 5, 2005, Pages 1567-1571

  Gulley, James L ^a   Figg, William D ^a   Steinberg, Seth M ^a   Carter, Jane ^a   Hussain, Maha H ^b,c   Dahut, William L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Clinical trial; Gonadorelin; Prostate specific antigen; Prostatic neoplasms; Testosterone

Indexed keywords

ANDROGEN; DIHYDROXYTESTOSTERONE; GONADORELIN AGONIST; GOSERELIN; HORMONE; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; UNCLASSIFIED DRUG;

ADULT; AGED; ANDROGEN BLOOD LEVEL; ARTICLE; CANCER HORMONE THERAPY; CANCER PATIENT; CIRCULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EVALUATION; GLEASON SCORE; HORMONE DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; TESTOSTERONE BLOOD LEVEL; TIME; TREATMENT WITHDRAWAL;

EID: 17144414951     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)68409-X     Document Type: Erratum

References (16)

1. Huggins, C. and Hodges, C.: Studies on prostatic cancer: the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res, 1: 293, 1941
2. Nejat, R. J., Rashid, H. H., Bagiella, E., Katz, A. E. and Benson, M. C.: A prospective analysis of time to normalization of serum testosterone after withdrawal of androgen deprivation therapy. J Urol, 164: 1891, 2000
3. Hall, M. C., Fritzsch, R. J., Sagalowsky, A. I., Ahrens, A., Petty, B. and Roehrborn, C. G.: Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer. Urology, 53: 898, 1999
4. Oefelein, M. G.: Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration. J Urol, 160: 1685, 1998
5. Oefelein, M. G.: Serum testosterone-based luteinizing hormone-releasing hormone agonist redosing schedule for chronic androgen ablation: a phase I assessment. Urology, 54: 694, 1999
6. Dahut, W.: Leuprolide or goserelin plus thalidomide compared with leuprolide or goserelin alone in treating patients with nonmetastatic prostate cancer. Available at http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid= 67700&version=patient&protocolsearchid=1083088. Accessed June 3, 2004
7. Stevens, M. J., Bell, D. R., Blome, S. A. and Begbie, S. D.: Prolonged hypogonadism after pulsed gonadotropin-releasing hormone agonist for prostate cancer. Lancet, 344: 274, 1994
8. Dearnaley, D. P., Norman, A. R. and Shahidi, M.: Re: Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration (letter to the editor). J Urol, 162: 170, 1999
9. Bruchovsky, N., Klotz, L. H., Sadar, M., Crook, J. M., Hoffart, D., Godwin, L. et al: Intermittent androgen suppression for prostate cancer: Canadian Prospective Trial and related observations. Mol Urol, 4: 191, 2000
10. Goldenfaerg, S. L., Gleave, M. E., Taylor, D. and Bruchovsky, N.: Clinical experience with intermittent androgen suppression in prostate cancer: minimum of 3 years' follow-up. Mol Urol, 3: 287, 1999
11. Gleave, M. E., Goldenberg, S. L., Sullivan, L. D., Warner, J. and La Bianca, S. E.: Recovery of testosterone levels after neoadjuvant hormonal therapy - comparison of 3 vs 8 months treatment prior to radical prostatectomy. J Urol, suppl., 163: 292, abstract 1297, 2000
12. Pickles, T., Graham, P. and Members of the British Columbia Cancer Agency Prostate Cohort Outcomes Initiative: What happens to testosterone after prostate radiation monotherapy and does it matter? J Urol, 167: 2448, 2002
13. Pouaha, J., Martin, S., Reichert-Penetrat, S., Trechot, P., Barbaud, A. and Schmutz, J. L.: Thalidomide and sexual dysfunction in men. Br J Dermatol, 146: 1112, 2002
14. Grosshans, E. and Illy, G.: Thalidomide therapy for inflammatory dermatoses. Int J Dermatol, 23: 598, 1984
15. Hamuryudan, V., Mat, C., Saip, S., Ozyazgan, Y., Siva, A., Yurdakul, S. et al: Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome. A randomized, double-blind, placebo- controlled trial. Ann Intern Med, 128: 443, 1998
16. Revuz, J., Guillaume, J. C., Janier, M., Hans, P., Marchand, C., Souteyrand, P. et al: Crossover study of thalidomide vs placebo in severe recurrent aphthous stomatitis. Arch Dermatol, 126: 923, 1990